Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 42-51

  Rudin, Charles M ^a   Pietanza, M Catherine ^a   Bauer, Todd M ^b,c   Ready, Neal ^d   Morgensztern, Daniel ^e   Glisson, Bonnie S ^f   Byers, Lauren A ^f   Johnson, Melissa L ^b,c   Burris, Howard A ^b,c   Robert, Francisco ^g   Han, Tae H ⁱ   Bheddah, Sheila ⁱ   Theiss, Noah ^h   Watson, Sky ^h   Mathur, Deepan ^h   Vennapusa, Bharathi ^h   Zayed, Hany ⁱ   Lally, Satwant ⁱ   Strickland, Donald K ^c   Govindan, Ramaswamy ^e   Dylla, Scott J ⁱ   Peng, Stanford L ⁱ   Spigel, David R ^b,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Tennessee Oncology PLLC   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ Stemcentrx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; ROVALPITUZUMAB TESIRINE; TRIACYLGLYCEROL LIPASE; TROPONIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DLL3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ACNE; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; COHORT ANALYSIS; CONJUNCTIVITIS; DECREASED APPETITE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART TAMPONADE; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOTENSION; HYPOXIA; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOCYTE; LIVER FUNCTION TEST; LUNG EDEMA; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PANCYTOPENIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PHOTOSENSITIVITY; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SMALL CELL LUNG CANCER; ST SEGMENT ELEVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR BLEEDING; VOMITING; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 85007506761     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30565-4     Document Type: Article

References (13)

1. 1 Ferlay, J, Soerjomataram, I, Ervik, M, et al. GLOBOCAN 2012 version 1.0: cancer incidence and mortality worldwide—IARC CancerBase no 11. http://globocan.iarc.fr, 2013 (accessed April 4, 2016).
2. 2 Fruh, M, De Ruysscher, D, Popat, S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:suppl 6 (2013), vi99–v105.
3. 3 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer, version 2, 2016, National Comprehensive Cancer Network, Fort Washington.
4. 4 Horita, N, Yamamoto, M, Sato, T, et al. Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients. Sci Rep, 5, 2015, 15437.
5. 5 Kalemkerian, GP, Akerley, W, Bogner, P, et al. Small cell lung cancer. J Natl Compr Cancer Netw 11 (2013), 78–98.
6. 6 Chapman, G, Sparrow, DB, Kremmer, E, Dunwoodie, SL, Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet 20 (2011), 905–916.
7. 7 Dunwoodie, SL, Henrique, D, Harrison, SM, Beddington, RS, Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 124 (1997), 3065–3076.
8. 8 Saunders, LR, Bankovich, AJ, Anderson, WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med, 7, 2015, 302ra136.
9. 9 Naidoo, J, Santos-Zabala, ML, Iyriboz, T, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer 17 (2016), e121–e129.
10. 10 Simos, D, Sajjady, G, Sergi, M, et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin Lung Cancer 15 (2014), 110–118.
11. 11 Antonia, SJ, López-Martin, JA, Bendell, J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 883–895.
12. 12 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
13. 13 Puzanov, I, Lee, W, Chen, AP, et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 17 (2011), 3794–3802.